Results 21 to 30 of about 209,011 (190)

Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease

Biology, 2012
Designing HIV-1 protease inhibitors that overcome drug-resistance is still a challenging task. In this study, four clinical isolates of multi-drug resistant HIV-1 proteases that exhibit resistance to all the US FDA-approved HIV-1 protease inhibitors and ...
Ladislau C. Kovari, Iulia A. Kovari, Joseph S. Brunzelle, Samuel J. Reiter, Zhigang Liu, Tamaria G. Dewdney, Yong Wang   +6 more
doaj   +1 more source

HIV-1 Protease Inhibitors [PDF]

Clinical Infectious Diseases, 2000
Treatment of human immunodeficiency virus type 1 (HIV-1) infection with regimens that include protease inhibitors (PIs) has contributed to marked improvements in HIV-related disease progression and mortality. Five PIs are approved by the US Food and Drug Administration and have potent activity in vitro.
openaire   +2 more sources

Molecular Basis for Drug Resistance in HIV-1 Protease

Viruses, 2010
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the ...
Celia A. Schiffer, Kelly Thayer, Ellen A. Nalivaika, Ayşegül Özen, Moses M. Prabu-Jeyabalan, Madhavi N.L. Nalam, Nancy M. King, Rajintha M. Bandaranayake, Jennifer F. Murzycki, Seema Mittal, Madhavi Kolli, Yufeng Cai, Akbar Ali   +12 more
doaj   +1 more source

HIV protease inhibitors and atherosclerosis [PDF]

Journal of Clinical Investigation, 2003
The advent of highly active antiretroviral therapy (HAART), including the use of HIV protease inhibitors (PIs) has significantly reduced the morbidity and mortality of AIDS in HIV infected patients. Unfortunately, the adverse effects of PIs, including dyslipidemia, lipodystrophy, insulin resistance, and premature atherosclerosis, are cause for concern ...
openaire   +2 more sources

HIV-2 Protease resistance defined in yeast cells

Retrovirology, 2006
Background Inhibitors of the HIV-1 Protease currently used in therapeutic protocols, have been found to inhibit, although at higher concentrations, the HIV-2 encoded enzyme homologue.
Raoult Didier, Audoly Gilles, M'Barek Najoua, Gluschankof Pablo   +3 more
doaj   +1 more source

Novel wild type and mutate HIV-1 protease inhibitors containing heteroaryl carboxamides in P2: Synthesis, biological evaluations and in silico ADME prediction

Results in Chemistry, 2023
The Virus HIV-1 infection still represents a serious disease even if actually it is transformed in chronic pathology. Considering the crucial role of the enzyme Protease in life cycle of HIV many efforts have been made in the research of new organic ...
Maria Francesca Armentano, Paolo Lupattelli, Faustino Bisaccia, Rosarita D'Orsi, Rocchina Miglionico, Ilaria Nigro, Alessandro Santarsiere, Federico Berti, Maria Funicello, Lucia Chiummiento   +9 more
doaj   +1 more source

Insights Into the Broad Cellular Effects of Nelfinavir and the HIV Protease Inhibitors Supporting Their Role in Cancer Treatment and Prevention

Current Opinion in Oncology, 2013
Purpose of review The development of HIV protease inhibitors more than two decades ago heralded a new era in HIV care, changing the infection from universally fatal to chronic but controllable.
S. Gantt, C. Casper, R. Ambinder
semanticscholar   +1 more source

Noninvasive High-Throughput Single-Cell Analysis of HIV Protease Activity Using Ratiometric Flow Cytometry

Sensors, 2013
To effectively fight against the human immunodeficiency virus infection/ acquired immunodeficiency syndrome (HIV/AIDS) epidemic, ongoing development of novel HIV protease inhibitors is required.
Rok Gaber, Andreja Majerle, Roman Jerala, Mojca Benčina   +3 more
doaj   +1 more source

HIV-1 Protease: Structural Perspectives on Drug Resistance

Viruses, 2009
Antiviral inhibitors of HIV-1 protease are a notable success of structure-based drug design and have dramatically improved AIDS therapy. Analysis of the structures and activities of drug resistant protease variants has revealed novel molecular mechanisms
Irene T. Weber, Johnson Agniswamy
doaj   +1 more source

Modulation of the LDL receptor and LRP levels by HIV protease inhibitors

Journal of Lipid Research, 2003
Inhibitors of the human immunodeficiency virus (HIV)-1 protease have proven to be effective antiretroviral drugs. However, patients receiving these drugs develop serious metabolic abnormalities, including hypercholesterolemia.
Huan Tran, Susan Robinson, Irina Mikhailenko, Dudley K. Strickland   +3 more
doaj   +1 more source